These sources guide standards, ingredient review and study design. They do not automatically substantiate an unfinished product.
2026 · Regulatory guidance
9 CFR Part 102 — licensing of veterinary biological products
USDA APHIS (Virus-Serum-Toxin Act, via eCFR)
Scope. Establishment and product licence requirements, and the data establishing purity, safety, potency and efficacy that an application must include.
Supports. Defines the pathway for any product presented as acting on immunity, and requires that all claims intended for labels and advertising be submitted as part of the application.
Does not establish. Does not apply to products marketed purely on nutrient contribution; conversely, no feed registration substitutes for a biologic licence where an immunity claim is made.
Primary source ↗2020 · Consensus recommendations
Consensus recommendations on calf- and herd-level passive immunity in dairy calves in the United States
Journal of Dairy Science
Scope. Replaces the binary pass/fail passive-transfer standard with four serum IgG categories and corresponding herd-level distribution goals.
Supports. The current US reference framework against which a colostrum program and any product used within it should be benchmarked and monitored.
Does not establish. Does not establish that any product or protocol moves calves between categories; it defines measurement thresholds and herd targets, not interventions.
Primary source ↗2019 · Controlled study
Comparison of oral, intravenous and subcutaneous fluid therapy for resuscitation of calves with diarrhea
Journal of Dairy Science
Scope. Randomised trial in calves with induced diarrhoea and dehydration comparing oral electrolyte solution against intravenous and subcutaneous routes.
Supports. Substantiates a properly formulated oral electrolyte as first-line rehydration for calves that retain a functional gut.
Does not establish. Does not reflect naturally occurring disease — diarrhoea was experimentally induced, acidemia was relatively mild, and treatment arms were not composition-matched.
Primary source ↗2018 · Controlled study
Serum protein electrophoretic pattern in neonatal calves treated with clinoptilolite
Molecules
Scope. 18 calves in three groups — colostrum alone, colostrum plus 0.5% clinoptilolite, colostrum plus 2% — dosed within two hours of birth and again at 12 and 24 hours.
Supports. The only head-to-head dose comparison in the colostrum window: at 30 hours the 0.5% group showed γ-globulin markedly above control, and the authors conclude the lower dose was the more effective of the two.
Does not establish. Does not measure IgG directly (γ-globulin is a proxy), uses six calves per arm, records no clinical endpoint, and shows the higher 2% dose performing worse than 0.5% — the effect is dose-critical, not linear.
Primary source ↗2016 · Systematic review
Failure of passive immune transfer in calves: a meta-analysis on the consequences and assessment of the economic impact
PLOS ONE
Scope. Meta-analysis of 68 published models quantifying adjusted risk of mortality, respiratory disease, diarrhoea and overall morbidity associated with failure of passive transfer.
Supports. Quantifies the health burden attached to failure of passive transfer, justifying it as a high-value development target.
Does not establish. Does not demonstrate that raising serum IgG by any given intervention delivers a proportional reduction in disease — the estimates are associational, with substantial heterogeneity.
Primary source ↗2016 · Systematic review
Diagnostic accuracy of refractometry for assessing bovine colostrum quality: a systematic review and meta-analysis
Journal of Dairy Science
Scope. Meta-analysis of 11 studies and 4,251 colostrum samples evaluating Brix refractometry against an IgG standard at different cutoffs.
Supports. Validates on-farm Brix as a screening input for colostrum quality decisions and quantifies the confidence each cutoff carries.
Does not establish. Does not establish that Brix predicts a calf's achieved serum IgG — it measures agreement with colostral IgG concentration only.
Primary source ↗2016 · Systematic review
Invited review: transitioning from milk to solid feed in dairy heifers
Journal of Dairy Science
Scope. Review of rumen ecosystem development, fermentation, papillae growth and rumination behaviour across the milk-to-solid-feed transition.
Supports. Informs starter formulation direction — specifically the balance between physically effective fibre and readily degradable carbohydrate.
Does not establish. Does not provide a validated numeric formulation specification, and as a narrative review applies no systematic risk-of-bias appraisal.
Primary source ↗2013 · Controlled study
Effect of feeding maternal colostrum or plasma-derived or colostrum-derived colostrum replacer on passive transfer, health and performance of preweaning heifer calves
Journal of Dairy Science
Scope. Three-arm trial comparing maternal colostrum against plasma-derived and colostrum-derived replacers, measuring apparent efficiency of absorption and passive-transfer adequacy.
Supports. Establishes that IgG source and absorption efficiency — not IgG mass alone — drive achieved serum IgG, a core formulation consideration.
Does not establish. Does not establish an upper bound on replacer performance, as it tested a single dose of each replacer rather than dose-matched IgG.
Primary source ↗2008 · Controlled study
Apparent efficiency of immunoglobulin absorption in newborn calves orally treated with zeolite
Acta Veterinaria
Scope. 60 Holstein calves in four groups, fed colostrum at two volumes with or without a 25% clinoptilolite suspension, measuring serum IgG and apparent efficiency of absorption.
Supports. The largest trial addressing clinoptilolite and colostral immunoglobulin directly: serum IgG at six hours was significantly higher with zeolite at the lower colostrum volume, and apparent efficiency of absorption was highest in that group — the mineral enhanced rather than impaired absorption.
Does not establish. Does not establish a mechanism, was not blinded, records no clinical outcomes such as morbidity or scours, and comes from a single research group.
Primary source ↗2008 · Controlled study
Clinical observations, biochemical data and postmortem findings in young dairy calves fed zeolite clinoptilolite with milk replacer
American Journal of Veterinary Research
Scope. 26 Holstein calves fed milk replacer with 0%, 0.5% or 2% clinoptilolite twice daily for 28 days, all necropsied.
Supports. The best tolerance dataset in neonatal calves — no gross lesions attributable to treatment at necropsy, and no adverse haematology or biochemistry.
Does not establish. Does not show any benefit; it was designed as a safety study, found no difference in bodyweight or average daily gain, and reported an unexplained increase in jejunal mucosal eosinophils in treated calves.
Primary source ↗2007 · Controlled study
Passive transfer of immunoglobulin G and preweaning health in Holstein calves fed a commercial colostrum replacer
Journal of Dairy Science
Scope. Trial comparing maternal colostrum against a commercial colostrum replacer regimen, measuring 24-hour serum IgG and passive-transfer adequacy.
Supports. Demonstrates directly that a marketed colostrum replacer can fail to deliver adequate passive transfer, establishing why product-specific validation is mandatory.
Does not establish. Does not generalise to all replacers — the result characterises one product and dosing regimen, not the category.
Primary source ↗
